Login to Your Account

Post-Panel Debate

Analysts Wonder How Affymax Will Fare Against Amgen

By Trista Morrison
Staff Writer

Friday, December 9, 2011
Affymax Inc. scored a big win on Wednesday when the FDA's Oncologic Drugs Advisory Committee voted 15-to-1 in favor of peginesatide for dialysis patients with anemia due to chronic kidney disease (CKD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription